[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564662":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"First Hospital of China Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HAIC plus Lenvatinib and PD-1 inhibitors",null,"Each patient should receive at least 2 cycles of HAIC and 1cycles of PD-1 plus Lenvatinib. The interval between HAIC and Lenvatinib plus PD-1 inhibitors should be within 2 weeks.",[13,14],"Procedure: hepatic artery infusion chemotherapy","Drug: Lenvatinib + PD-1 monoclonal antibody",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"PROCEDURE","hepatic artery infusion chemotherapy","Hepatic arterial infusion chemotherapy including FOLFOX and RALOX",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DRUG","Lenvatinib + PD-1 monoclonal antibody","PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab",[9],[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Jiaxi Liu","CONTACT","+8618940279150","dmuvictor@163.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The first hospital of China medical university","RECRUITING","Shenyang","Liaoning","110000","China","CN",{"type":42,"coordinates":43},"Point",[44,45],123.43278,41.79222,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":30,"phoneExt":10,"email":31},"Haibo Shao",{"type":51,"investigatorFullName":49,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor, MD, PhD","100564662","haic-in-combination-with-pd-1-inhibitors-and-lenvatinib-for-intermediate-and-advanced-hcc-after-the-failure-of-systemic-therapy-recommended-by-bclc-100564662",false,"NCT06632093","HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of portal vein tumor thrombus;\n3. Has received previous systemic therapy recommended for HCC by BCLC, and the systemic therapy failed;\n4. Both PD-1inhibitors and Lenvatinib patients received only include marketed drugs but are not limited to HCC approval;\n5. HAIC was performed after the first PD-1 inhibitor\u002F Lenvatinib treatment or before treatment;\n6. Received at least 2 cycles of HAIC；\n7. Has repeated measurable intrahepatic lesions;\n8. Child-Pugh class A or B.\n\nExclusion Criteria:\n\n1. The interval between the failure of systemic therapy and the beginning of combination therapy longer than 3 months;\n2. With other malignant tumors;\n3. Unable to meet criteria of combination timeframe described above.","ALL","18 Years","75 Years",{"count":64,"type":65},84,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.",[69,70,71,72,73,74],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Hepatic Arterial Infusion Chemotherapy","Lenvatinib","PD-1","Systemic Therapy","2024-10-06",{"date":77,"type":78},"2024-10-08","ACTUAL",{"date":80,"type":78},"2024-09-16",{"date":82,"type":65},"2025-12-30",{"name":5,"class":6},1]